FDA extends review period for Humacyte’s vascular trauma treatment ATEV

The U.S. Food and Drug Administration’s review of Humacyte, Inc.'s innovative vascular trauma treatment, known as the acellular tissue engineered vessel (ATEV), has hit an ... Read More